Cantor Fitzgerald analyst Charles Duncan lowered the price target on Marinus Pharmaceuticals (NASDAQ: MRNS) to $13.00 (from $28.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE